Cochrane · systematic review · CD010298
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
Martí‐Carvajal, AJ, Anand, V, Solà, I · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 8.3%Very low 0 · 0%Low 11 · 91.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ruxolitinib compared with placebo for treating myelofibrosis
Population: Patients with treating MF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (number of deaths at Ruxolitinib vs placebo | HR 0.51 [0.27, 0.98] | 1 study · 309 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival ‐ not measured Ruxolitinib vs placebo | no estimate extracted | 1 study · 309 participants | Ungraded |
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute Ruxolitinib vs placebo | RR 9.74 [2.32, 40.96] | 1 study · 306 participants | Low Downgraded: risk of bias, imprecision |
Safety (AE, adverse drug reaction): neutropenia Grades 3 or 4 according to National Cancer Institute Ruxolitinib vs placebo | RR 3.57 [1.02, 12.55] | 1 study · 306 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form Ruxolitinib vs placebo | RR 8.82 [4.4, 17.69] | 1 study · 309 participants | Low Downgraded: risk of bias, imprecision |
Reduction in spleen size Magnetic resonance imaging or computed tomography Ruxolitinib vs placebo | RR 64.58 [9.08, 459.56] | 1 study · 309 participants | Low Downgraded: risk of bias, imprecision |
Ruxolitinib compared with best available therapy for treating myelofibrosis
Population: Patients with treating MF
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (number of deaths at Ruxolitinib vs best available therapy | HR 0.7 [0.2, 2.47] | 1 study · 219 participants | Low Downgraded: risk of bias, imprecision |
Progression Free Survival (number of patients who had progression at Ruxolitinib vs best available therapy | HR 0.81 [0.47, 1.39] | 1 study · 219 participants | Low Downgraded: risk of bias, imprecision |
Safety (AE, adverse drug reaction): anemia Grades 3 or 4 according to National Cancer Institute Ruxolitinib vs best available therapy | RR 1.35 [0.91, 1.99] | 1 study · 219 participants | Low Downgraded: risk of bias, imprecision |
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute Ruxolitinib vs best available therapy | RR 1.2 [0.44, 3.28] | 1 study · 219 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life European Organization for Research and Treatment of Cancer quality of life questionnaire core model. Scores ranges from 0 to 100. Scale from: 0 to 100. Ruxolitinib vs best available therapy | no estimate extracted | 1 study · 96 participants | Low Downgraded: risk of bias, imprecision |
Reduction in spleen size Magnetic resonance imaging or computed tomography Ruxolitinib vs best available therapy | RR 41.78 [2.61, 669.75] | 1 study · 219 participants | Low Downgraded: risk of bias, imprecision |